TrialCancer science2021

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.

Yasuhito Terui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.